The legacy success of copyright’s flagship drug has undeniably shaped the drug landscape. However, putting money in companies heavily focused on copycat drugs and the declining patent protection https://active-bookmarks.com/story21281301/the-blue-pill-and-drugmakers-a-risky-opportunity